Initiative gets $1.3 million to verify findings of 50 high-profile cancer papers
One of the major concerns in biomedical research today is that many basic findings cannot be easily replicated by other labs. Might the literature be stuffed with flukes and unrepeatable results, not sufficiently checked out before publication, and rarely repeated by other labs? Such doubts have increased in the past year, especially after scientists at Amgen and Bayer reported that they had been unable to reproduce the vast majority of ‘landmark’ papers describing promising approaches to treat disease. Read more
Recent comments on this blog
Experiments reveal that crabs and lobsters feel pain
US research ethics agency upholds decision on informed consent
Chemistry credit disputes under the spotlight
Chemistry credit disputes under the spotlight
Contamination created controversial ‘acid-induced’ stem cells